Advertisement
Advertisement
U.S. markets open in 2 hours 54 minutes
Advertisement
Advertisement
Advertisement
Advertisement

LexaGene Holdings Inc. (LXXGF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1815-0.0215 (-10.59%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2030
Open0.1997
BidN/A x N/A
AskN/A x N/A
Day's Range0.1787 - 0.1997
52 Week Range0.0500 - 0.3200
Volume222,148
Avg. Volume147,038
Market Cap25.527M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateJan 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for LXXGF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • LEXAGENE HOLDINGS INC
    NKTR: What does Argus have to say about NKTR?NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    LexaGene’s MiQLab System Detects Mycoplasma at Minute Levels, Rousing Additional Interest from BioPharma Customers

    BEVERLY, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLabTM System for automated, genetic testing, is pleased to announce exciting news regarding the ability of the MiQLab System to detect Mycoplasma at minute levels. Dr. Jack Regan, CEO and Founder of LexaGene commented, “In the process of completing the follow-on feasibility study with one o

  • GlobeNewswire

    BioPharma Engages LexaGene in Second Feasibility Study

    Cancels Plans to Reprice Meridian’s WarrantsBEVERLY, Mass. , Dec. 16, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, is pleased to announce the large biopharma company (>$100B Market Cap) that previously purchased a MiQLab System has engaged LexaGene in a second statement of work (“SOW”) that builds off of the previou

  • GlobeNewswire

    LexaGene Holdings Proposes to Amend Warrants Terms

    BEVERLY, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has commercialized the MiQLab® System for automated, genetic testing, announces that it intends to amend the exercise price of certain common share purchase warrants (the “Warrants”) originally issued on February 7 and February 18, 2022 to Meridian LGH Holdings, LLC and expiry five years after the date of issue. An

Advertisement
Advertisement